Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Inge van der Werf

Postdoc
Inge van der Werf
Inge van der Werf

Bone Marrow Failure in Pediatric Patients

Phone 088 97 25 186

Our mission is to unravel the basic mechanisms by which human hematopoietic stem cells (re-)generate blood, and to translate this knowledge into therapies to improve hematopoiesis in children with intrinsic or acquired bone marrow failure, or in those undergoing HSCT.

 

  • Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

    • sep. 2021
    • Inge, Van Der Werf, et al
    • Blood Advances
  • SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia

    • sep. 2021
    • Inge, van der Werf, et al
    • Leukemia
  • Author Correction

    • sep. 2021
    • Inge, van der Werf, et al
    • Leukemia
  • Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia

    • aug. 2021
    • Joost B, Koedijk, et al
    • Cancers
  • Maturation state-specific alternative splicing in flt3-itd and npm1 mutated aml

    • aug. 2021
    • Anna, Wojtuszkiewicz, et al
    • Cancers
View all publications